|
Thyroid Neoplasm
|
0.460 |
GeneticVariation
|
disease |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
|
Thyroid Neoplasm
|
0.460 |
Biomarker
|
disease |
BEFREE |
Some somatic oncogene mutations (BRAF, NRAS, HRAS, KRAS) as well as gene translocations (RET/PTC, PAX8/PPAR-gamma) have been associated with the development of thyroid cancer.
|
26259532 |
2016 |
|
Thyroid Neoplasm
|
0.460 |
CausalMutation
|
disease |
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
|
Thyroid Neoplasm
|
0.460 |
CausalMutation
|
disease |
CLINVAR |
Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.
|
23406027 |
2013 |
|
Thyroid Neoplasm
|
0.460 |
GeneticVariation
|
disease |
BEFREE |
No mutation was found in any of the thyroid tumor tissue samples, but we frequently detected polymorphism at nucleotide 81 (T > C) in exon 1 of HRAS gene.
|
23150177 |
2013 |
|
Thyroid Neoplasm
|
0.460 |
CausalMutation
|
disease |
CLINVAR |
Phase II trial of sorafenib in metastatic thyroid cancer.
|
19255327 |
2009 |
|
Thyroid Neoplasm
|
0.460 |
CausalMutation
|
disease |
CLINVAR |
Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma.
|
19773371 |
2009 |
|
Thyroid Neoplasm
|
0.460 |
GeneticVariation
|
disease |
LHGDN |
BRAF and K-RAS mutation in a Greek papillary and medullary thyroid carcinoma cohort.
|
18383861 |
2008 |
|
Thyroid Neoplasm
|
0.460 |
GeneticVariation
|
disease |
LHGDN |
Familial non-medullary thyroid carcinoma (FNMTC): analysis of fPTC/PRN, NMTC1, MNG1 and TCO susceptibility loci and identification of somatic BRAF and RAS mutations.
|
18310288 |
2008 |
|
Thyroid Neoplasm
|
0.460 |
CausalMutation
|
disease |
CLINVAR |
Hyperactive Ras in developmental disorders and cancer.
|
17384584 |
2007 |
|
Thyroid Neoplasm
|
0.460 |
GeneticVariation
|
disease |
BEFREE |
Using polymerase chain reaction and sequence-specific oligonucleotide hybridization, the frequency of three ras oncogene mutations (N-ras, Ha-ras, and K-ras) in thyroid tumors (25 adenomas, 16 follicular carcinomas, and 22 papillary carcinomas) was investigated in both iodide-deficient and iodide-sufficient areas.
|
2021946 |
1991 |
|
Thyroid Neoplasm
|
0.460 |
GeneticVariation
|
disease |
BEFREE |
Thus the a4 and a2 alleles of c-Ha-ras-1 may perhaps be viewed as genetic markers of predisposition to lung, ovarian and thyroid cancer, respectively, in combination with other clinical parameters.
|
1980342 |
1990 |
|
Thyroid Neoplasm
|
0.460 |
Biomarker
|
disease |
CTD_human |
Agent-specific ras oncogene activation in rat thyroid tumours.
|
3078959 |
1988 |